GlassScriptPhysician profile
Faraz Berjis
NPI 1366553885
$1,692.86
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,403 · 2020: $273 · 2021: $16.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $339.90 | 2019-2020 | |
| Abbvie INC. | $276.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $273.92 | 2019-2020 | |
| Allergan, INC. | $151.29 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.37 | 2019-2020 | |
| Pfizer INC. | $100.81 | 2019 | |
| Medtronic USA, INC. | $81.87 | 2019 | |
| Intercept Pharmaceuticals, INC. | $53.09 | 2019-2020 | |
| Shionogi INC | $43.78 | 2019 | |
| Daiichi Sankyo INC. | $39.29 | 2019-2020 | |
| Gilead Sciences, INC. | $32.98 | 2019 | |
| Qol Medical, LLC | $32.93 | 2019 | |
| Alfasigma USA, INC. | $26.13 | 2020 | |
| Endo Pharmaceuticals INC. | $20.71 | 2019 | |
| Boston Scientific Corporation | $19.27 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $18.77 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.77 | 2019 | |
| Merck Sharp & Dohme LLC | $16.56 | 2019 | |
| Celgene Corporation | $16.48 | 2021 | |
| Csl Behring | $15.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faraz Berjis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.